Pharma’s Top Employers in 2012
The 2012 Science Careers Top Employers Survey, conducted by the journal Science, examined the best places to work in pharma and biotech. Regeneron Pharma ranked No. 1 followed by Vertex Pharma (2), Genentech (3), and Novo Nordisk (4). These companies made the list because they continue to hire scientists and invest in R&D, and by helping their employees live balanced, healthy lives. Rounding out the top 10 were: Monsanto (5), Millennium (6), Boehringer Ingelheim (7), Roche (8), Biogen Idec (9) and DuPont (10).
Customer Satisfaction with Mail-Order Pharmacies Drops
According to a J.D. Powers & Associates Report, overall satisfaction with mail-order pharmacies averaged 792 (on a 1,000-point scale), which is 22 points below the average overall satisfaction score for brick and mortar pharmacies in 2012, and 14 points lower than the average in 2011. In contrast, overall satisfaction with brick and mortar pharmacies held steady with an average score of 814 in 2012. Health Mart, Kaiser Permanente Pharmacy, Publix and Sam’s Club ranked highest among brick and mortar pharmacies in customer satisfaction.
ghg Introduces Digital Dx
Introduced by grey healthcare group, Digital Dx is a new methodology for measuring, tracking and maximizing the power of brands, companies and market issues across all online media, including websites, social media, search engines and mobile. Erin Byrne, Managing Partner and Chief Engagement Officer at ghg, believes that Digital Dx fills a market gap with a best-practice approach that gives healthcare marketers a thorough evaluation of their digital presence and concrete steps that they can take to increase impact and ROI.
EvaluatePharma Launches EvaluateMedTech
EvaluateMedTech, a new intelligence service, allows companies, investment banks, consulting companies and service providers to easily track and benchmark the medical device and diagnostic industry in a one-stop, up-to-date online platform. Unique insights derived from public company information, equity analyst reports, regulatory approvals, clinical trials, press releases and venture financing data, among other sources, help provide solutions to business problems.
10 Pharma Companies Join Forces
Ten leading pharma companies—Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech, and Sanofi—formed a new non-profit organization called TranCelerate BioPharma, to identify and solve common drug development challenges involved with conducting clinical studies and bringing new medicines to patients faster. Five projects were selected by the group for funding and development.
AstraZeneca Launches Social Media Initiative
LabTalk is an online forum for scientists and researchers to share and discuss cutting-edge science and innovative approaches, from drug discovery to commercialization. Oliver Stohlmann, Vice President of R&D Communications at AstraZeneca, says that LabTalk will not only raise the profile of innovative science, but will create a platform to engage new and existing peers, showcase their scientists’ work and build content to tell the company’s R&D story. LabTalk can be found at: labtalk.astrazeneca.com.
Appature Receives New Patent
Appature Nexus, Appature’s cloud-based software solution, integrates critical marketing functionality and big data infrastructure to enable the new model of data-driven marketing with a simple user-interface not available in existing software products. With Appature Nexus, marketers can target customers with personalized communications through email, mobile and several other marketing channels, as well as access real-time reporting to optimize campaigns.
Teva Pharmaceuticals Signs Deal for Huntexil
Teva, an Israel-based generic drug company will pay $26M over six months to Denmark-based biopharma company NeuroSearch A/S to acquire all rights and assets to drug candidate, Huntexil. The drug helps to treat hand movement, balance and gait disturbances caused by Huntington disease. Teva plans to design and complete clinical studies to determine its potential.
